Kitz, Julia

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Azizian, A."],["dc.contributor.author","Bernhardt, M."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Koenig, A."],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T10:20:53Z"],["dc.date.available","2018-11-07T10:20:53Z"],["dc.date.issued","2016"],["dc.format.extent","75"],["dc.identifier.isi","000371353700239"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41971"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Heterogeneity of KRAS Mutation Status in Rectal Cancer"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","190"],["dc.contributor.author","Roedel, Franz"],["dc.contributor.author","Wieland, Ulrike"],["dc.contributor.author","Fraunholz, I."],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Weiss, C."],["dc.contributor.author","Wirtz, Ralph M."],["dc.contributor.author","Balermpas, P."],["dc.contributor.author","Fokas, Emmanouil"],["dc.contributor.author","Roedel, Claus"],["dc.date.accessioned","2018-11-07T09:38:35Z"],["dc.date.available","2018-11-07T09:38:35Z"],["dc.date.issued","2014"],["dc.identifier.isi","000337052500040"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33093"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","20th Annual Congress of the German-Society-for-Radiation-Oncology"],["dc.relation.eventlocation","Dusseldorf, GERMANY"],["dc.title","HPV-16 viral load and p16(INK4a) expression as a predictive marker for tumor control and survival after definitive chemoradiotherapy for patients with anal carcinoma"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","190"],["dc.contributor.author","Tehrany, Narges"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Turek, I."],["dc.contributor.author","Hinsche, T."],["dc.contributor.author","Droege, Leif Hendrik"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.date.accessioned","2018-11-07T09:38:35Z"],["dc.date.available","2018-11-07T09:38:35Z"],["dc.date.issued","2014"],["dc.format.extent","28"],["dc.identifier.isi","000337052500059"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33094"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","20th Annual Congress of the German-Society-for-Radiation-Oncology"],["dc.relation.eventlocation","Dusseldorf, GERMANY"],["dc.relation.issn","1439-099X"],["dc.relation.issn","0179-7158"],["dc.title","Hohergradige acute Organtoxizitat with proven HPV infection as a positive prognostic factor in patients with HNSCC"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1283"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","American Journal of Surgical Pathology"],["dc.bibliographiccitation.lastpage","1289"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Gauss, Korbinian"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Wolff, Hendrik"],["dc.contributor.author","Scheel, Andreas H."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2021-06-01T10:47:01Z"],["dc.date.available","2021-06-01T10:47:01Z"],["dc.date.issued","2013"],["dc.identifier.doi","10.1097/PAS.0b013e3182886ced"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85449"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","0147-5185"],["dc.title","Lymph Node Metastases in Rectal Cancer After Preoperative Radiochemotherapy"],["dc.title.alternative","Impact of Intramesorectal Distribution and Residual Micrometastatic Involvement"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","451"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Radiotherapy and Oncology"],["dc.bibliographiccitation.lastpage","457"],["dc.bibliographiccitation.volume","108"],["dc.contributor.author","Salendo, Junius"],["dc.contributor.author","Spitzner, Melanie"],["dc.contributor.author","Kramer, Frank"],["dc.contributor.author","Zhang, X."],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Kaulfuß, Silke"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Dobbelstein, Matthias"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T09:20:18Z"],["dc.date.available","2018-11-07T09:20:18Z"],["dc.date.issued","2013"],["dc.description.abstract","Background and purpose: Preoperative chemoradiotherapy (CRT) represents the standard treatment for locally advanced rectal cancer. Tumor response and progression vary considerably. MicroRNAs represent master regulators of gene expression, and may therefore contribute to this diversity. Material and methods: Genome-wide microRNA (miRNA) profiling was performed for 12 colorectal cancer (CRC) cell lines and an individual in vitro signature of chemoradiosensitivity was established. Functional relevance of selected miRNAs was established by transfecting miRNA-mimics into SW480 and SW837 cells. The prognostic value of selected miRNAs was assessed in 128 pretherapeutic patient biopsies. Results: Thirty-six miRNAs were identified to significantly correlate with sensitivity to CRT (Q < 0.05) including miR-320a and other miRNAs involved in the MAPK-, TGF- and Wnt-pathway. Transfection of selected miRNAs (let-7g, miR-132, miR-224, miR-320a) each induced a shift of sensitivity. High expression of let-7g was associated with a good prognosis in rectal cancer patients (P = 0.03). Conclusions: This is the first report of a miRNA expression signature for in vitro chemoradiosensitivity of cell lines. Many of the identified miRNAs have not been linked to the response to CRT and may represent potential molecular targets to sensitize resistant cancers. If further validated, let7g expression may serve as predictive biomarker. (C) 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 108 (2013) 451-457"],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft [KFO 179]"],["dc.identifier.doi","10.1016/j.radonc.2013.06.032"],["dc.identifier.isi","000327004700015"],["dc.identifier.pmid","23932154"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28850"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.publisher.place","Clare"],["dc.relation.conference","13th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology"],["dc.relation.eventlocation","Ermatingen, SWITZERLAND"],["dc.relation.issn","0167-8140"],["dc.title","Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a,-224,-132 and let7g"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","278"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","International Journal of Cancer"],["dc.bibliographiccitation.lastpage","288"],["dc.bibliographiccitation.volume","136"],["dc.contributor.author","Roedel, Franz"],["dc.contributor.author","Wieland, Ulrike"],["dc.contributor.author","Fraunholz, Ingeborg"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Weiss, Christian"],["dc.contributor.author","Wirtz, Ralph M."],["dc.contributor.author","Balermpas, Panagiotis"],["dc.contributor.author","Fokas, Emmanouil"],["dc.contributor.author","Roedel, Claus"],["dc.date.accessioned","2018-11-07T10:02:08Z"],["dc.date.available","2018-11-07T10:02:08Z"],["dc.date.issued","2015"],["dc.description.abstract","As the detection rate of HPV-DNA in anal carcinoma commonly exceeds 90%, a comparison between sole HPV-positive and HPV-negative cancers with respect to treatment response following chemoradiotherapy (CRT) and long-term oncological outcome is challenging. Against this background, we aimed to assess HPV types and HPV DNA load in formalin-fixed paraffin-embedded tissue (FFPE) of 95 patients treated with standard CRT for anal cancer to correlate viral load (/> median) with local failure, distant metastases, cancer-specific (CSS) and overall survival (OS) rates. Various clinicopathologic parameters and the immunohistochemical marker p16(INK4a) were evaluated for any correlation with HPV16 DNA load and were included in uni- and multivariate analyses. The overall prevalence of HPV DNA was 95.8% with HPV16 monoinfection being the most commonly encountered HPV type (78.9%), followed by HPV16 and 31, 35, 39, 44, 58, 66 and 81 dual infection in 9 patients (9.5%). HPV16 DNA load was significantly associated with p16(INK4a) expression (p = 0.001). Patients with HPV16 DNA loadmedian and low p16(INK4a) expression showed significantly worse local control (HPV16 DNA load: univariate p = 0.023, multivariate p = 0.042; p16(INK4a): univariate p = 0.021), and OS (HPV16 DNA load: univariate p = 0.02, multivariate p = 0.03). Moreover, a combined HPV16 DNA load and p16(INK4a) variable revealed a significant correlation to decreased local failure, and increased CSS and OS (p = 0.019, p = 0.04 and p = 0.031). In conclusion, these data indicate that HPV16 DNA load and p16(INK4a) expression are significant prognostic factors for local tumor control and overall survival of patients with anal SCC following CRT. What's new? As the detection rate of HPV-DNA in anal carcinoma commonly exceeds 90%, comparing solely HPV-positive and HPV-negative cancers with respect to treatment response following chemoradiotherapy and long-term oncological outcome is challenging. Here, the authors demonstrate for the first time that low initial HPV16 DNA load and low/negative p16INK4a expression in pretreatment biopsies are significant risk factors for local failure and decreased overall survival in patients treated with standard chemoradiotherapy. The findings provide a rationale for the implementation of a standardized HPV molecular and immunohistochemical evaluation protocol in clinical trials in patients with anal carcinoma that may require alternative treatment strategies."],["dc.identifier.doi","10.1002/ijc.28979"],["dc.identifier.isi","000344596600006"],["dc.identifier.pmid","24839133"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38169"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley"],["dc.relation.issn","1097-0215"],["dc.relation.issn","0020-7136"],["dc.title","Human papillomavirus DNA load and p16(INK4a) expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","564"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Surgery"],["dc.bibliographiccitation.lastpage","570"],["dc.bibliographiccitation.volume","151"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Rüschoff, Josef R."],["dc.contributor.author","Hartmann, Arndt"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Müller-Dornieden, Annegret"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Schneider-Stock, Regine"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T09:11:55Z"],["dc.date.available","2018-11-07T09:11:55Z"],["dc.date.issued","2012"],["dc.description.abstract","Background. Locally advanced rectal cancers are treated with preoperative radiochemotherapy (RCT). However, subsets of patients have no benefit from preoperative treatment. Since epigenetic modifications, including DNA methylation, may influence response to neoadjuvant treatment we studied the CpG island methylator phenotype (CIMP) in patients who received a 5-fluouracil based RCT Methods. One hundred fifty patients, with locally advanced rectal cancer, treated within a phase HI clinical trial (CAO/ARO/AIO-94 and -04), were included in this analysis. CIMP was assessed by methylation specific PCR (MSP) using RUNX3, SOCS1, NEUROG1, IGF2, and CACNA1G as a marker panel. Loss of mismatch repair gene (MMR) expression was assessed by immunohistochemistry for a subset of patients. KRAS and BRAF mutation status were assessed using Sanger sequencing. Results. The CIMP status could be established in all 150 patients. Fifteen (10%) revealed CIMP positivity >= 3 methylated promoters), whereas 135 patients (90%) where classified as CIMP negative. Analysis for MMR status. did not reveal any microsatellite instability (MSI). A single mutation of the BRAF gene (D594G) was detected. The KRAS gene (exon 1, 2, and 3) was mutated in 65 tumors (43%) but was not correlated to a specific CIMP status. Three- and 5-year disease-free survival was notably worse in CIMP positive patients (56% and 0% vs 80% and 75%; P < .01) suggesting an increased likelihood of poor clinical outcome (HR 5.5; 95% CI: [2.1, 13.9]). Conclusion. CIMP positivity, defined by methylation of at least 3 specific gene promoters, is an infrequent event in locally advanced rectal cancer. However it increases the likelihood of distant metastases. Therefore, the CIMP status may be included as a molecular marker for the identification of high-risk patients and might contribute to individual treatment stratification. (Surgery 2012;151:564-70.)"],["dc.identifier.doi","10.1016/j.surg.2011.08.013"],["dc.identifier.isi","000301996600010"],["dc.identifier.pmid","22001634"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26829"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Mosby-elsevier"],["dc.relation.issn","0039-6060"],["dc.title","CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","522"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","American Journal of Surgical Pathology"],["dc.bibliographiccitation.lastpage","531"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Styczen, Hanna"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Roedel, Claus"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Talaulicar, Recca"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Rüschoff, Josef R."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:26:46Z"],["dc.date.available","2018-11-07T09:26:46Z"],["dc.date.issued","2013"],["dc.description.abstract","In patients with advanced rectal cancer (cUICC II and III) multimodality therapy resulted in better long-term local tumor control. Ongoing clinical trials are focusing on therapy intensification to improve disease-free (DFS) and cancer-specific survival (CSS), the integration of biomarkers for prediction of individual recurrence risk, and the identification of new targets. In this context, we investigated HER-2, a member of the epidermal growth factor receptor family, whose expression pattern and role was unclear in rectal cancer. A total of 264 patients (192 male, 72 female; median age 64 y) received standardized multidisciplinary treatment according to protocols of phase II/III trials of the German Rectal Cancer Study Group. HER-2 status was determined in pretherapeutic biopsies and resection specimens using immunohistochemistry scoring and detection of silver in situ hybridization amplification. Tumors with an immunohistochemistry score of 3(+) or silver in situ hybridization ratios of >= 2.0 were classified HER-2 positive; these results were correlated with clinicopathologic parameters [eg, resection (R) status, nodal status ((y)pN)], DFS, and CSS. Positive HER-2 status was found in 12.4% of biopsies and in 26.7% of resected specimens. With a median follow-up of 46.5 months, patients with HER-2 positivity showed in trend a better DFS (P = 0.1) and a benefit in CSS (P = 0.03). The 5-year survival rate was 96.0% (HER-2 positive) versus 80.0% (HER-2 negative). In univariate and multivariate analyses, HER-2 was an independent predictor for CSS (0.02) along with the (y)pN status (P < 0.00001) and R status (P = 0.011). HER-2 amplification is detectable in a relevant proportion (26.7%) of rectal cancer patients. For the development of innovative new therapies, HER-2 may represent a promising target and should be further assessed within prospective clinical trials."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft [KFO 179-2]"],["dc.identifier.doi","10.1097/PAS.0b013e318272ff4d"],["dc.identifier.isi","000316184000006"],["dc.identifier.pmid","23282976"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30374"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1532-0979"],["dc.relation.issn","0147-5185"],["dc.title","Frequency of HER-2 Positivity in Rectal Cancer and Prognosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","568"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Journal of Molecular Sciences"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Epping, Ingo"],["dc.contributor.author","Kramer, Frank"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Bernhardt, Markus"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Salinas, Gabriela"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Beissbarath, Tim"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T10:16:01Z"],["dc.date.available","2018-11-07T10:16:01Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Patients with locally advanced rectal cancer are treated with preoperative chemoradiotherapy followed by surgical resection. Despite similar clinical parameters (uT2-3, uN+) and standard therapy, patients' prognoses differ widely. A possible prediction of prognosis through microRNAs as biomarkers out of treatment-naive biopsies would allow individualized therapy options. Methods: Microarray analysis of 45 microdissected preoperative biopsies from patients with rectal cancer was performed to identify potential microRNAs to predict overall survival, disease-free survival, cancer-specific survival, distant-metastasis-free survival, tumor regression grade, or nodal stage. Quantitative real-time polymerase chain reaction (qPCR) was performed on an independent set of 147 rectal cancer patients to validate relevant miRNAs. Results: In the microarray screen, 14 microRNAs were significantly correlated to overall survival. Five microRNAs were included from previous work. Finally, 19 miRNAs were evaluated by qPCR. miR-515-5p, miR-573, miR-579 and miR-802 demonstrated significant correlation with overall survival and cancer-specific survival (p<0.05). miR-573 was also significantly correlated with the tumor regression grade after preoperative chemoradiotherapy. miR-133b showed a significant correlation with distant-metastasis-free survival. miR-146b expression levels showed a significant correlation with nodal stage. Conclusion: Specific microRNAs can be used as biomarkers to predict prognosis of patients with rectal cancer and possibly stratify patients' therapy if validated in a prospective study."],["dc.identifier.doi","10.3390/ijms17040568"],["dc.identifier.isi","000374585300147"],["dc.identifier.pmid","27092493"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13222"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40949"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Mdpi Ag"],["dc.relation.issn","1422-0067"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Prognostic Value of MicroRNAs in Preoperative Treated Rectal Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","8123"],["dc.bibliographiccitation.issue","18"],["dc.bibliographiccitation.journal","Oncotarget"],["dc.bibliographiccitation.lastpage","8135"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Claus, Rainer"],["dc.contributor.author","Weichenhan, Dieter"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Wolff, Hendrik A"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Doyen, Jerome"],["dc.contributor.author","Gérard, Jean-Pierre"],["dc.contributor.author","Johnsen, Steven Arthur"],["dc.contributor.author","Plass, Christoph"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.date.accessioned","2021-06-01T10:48:31Z"],["dc.date.available","2021-06-01T10:48:31Z"],["dc.date.issued","2014"],["dc.description.abstract","In locally advanced rectal cancer a preoperative predictive biomarker is necessary to adjust treatment specifically for those patients expected to suffer relapse. We applied whole genome methylation CpG island array analyses to an initial set of patients (n=11) to identify differentially methylated regions (DMRs) that separate a good from a bad prognosis group. Using a quantitative high-resolution approach, candidate DMRs were first validated in a set of 61 patients (test set) and then confirmed DMRs were further validated in additional independent patient cohorts (n=71, n=42). We identified twenty highly discriminative DMRs and validated them in the test set using the MassARRAY technique. Ten DMRs could be confirmed which allowed separation into prognosis groups (p=0.0207, HR=4.09). The classifier was validated in two additional cohorts (n=71, p=0.0345, HR=3.57 and n=42, p=0.0113, HR=3.78). Interestingly, six of the ten DMRs represented regions close to the transcriptional start sites of genes which are also marked by the Polycomb Repressor Complex component EZH2. In conclusion we present a classifier comprising 10 DMRs which predicts patient prognosis with a high degree of accuracy. These data may now help to discriminate between patients that may respond better to standard treatments from those that may require alternative modalities."],["dc.identifier.doi","10.18632/oncotarget.2347"],["dc.identifier.isi","000348030900013"],["dc.identifier.pmid","25261372"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11888"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85964"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Impact Journals Llc"],["dc.relation.eissn","1949-2553"],["dc.relation.issn","1949-2553"],["dc.rights","CC BY 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/3.0"],["dc.title","Identification of a DNA methylation signature to predict disease-free survival in locally advanced rectal cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]